Trial Profile
A Single Center, Randomized, Double-blind, Active Controlled, Parallel Group Study to Demonstrate Non-inferiority of a Fixed Dose Combination of 5 mg Amlodipine and 80 mg Valsartan to 160 mg Valsartan in the Treatment of Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Amlodipine/valsartan; Valsartan
- Indications Hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 18 Oct 2011 Planned end date changed from 1 Nov 2010 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 18 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Feb 2010 New trial record